Skip to main content
Adriene Marques)

R&D Capabilities

Excellence in Research & Development

CSL's mission is to discover, develop and deliver our innovative therapies that improve the patients' quality of life. Our scientists and researchers are recognised for their contributions to developing breakthrough medicines that have the potential to help millions of patients worldwide.

We are grateful to the patients, volunteers and researchers that participate in the clinical trials for testing our potential biotherapies. All contributions have helped better our understanding of diseases.

CSL's R&D capabilities are focused in four major areas:

close up image of product bottles

Plasma Fractionation

CSL’s clinical research activities make products available to patients worldwide and identify novel therapeutic uses for plasma proteins.

As a leading manufacturer and developer of therapeutics derived from human plasma, CSL is committed to maintaining the highest product safety standards and to continually improving manufacturing effectiveness. CSL's research programs are focused on developing novel plasma proteins with improved efficacy and enhanced convenience.

image of a scientist filling a vial

Recombinant Technology

We have extensive experience in the production, clinical development and launch of recombinant coagulation factors.

We are also focused on the development, production and testing of novel monoclonal antibodies (mAbs) to treat inflammatory diseases (CSL324), hereditary angioedema (CSL312) and target fatty acid metabolism (CSL346).

In collaboration with Momenta Pharmaceuticals, we are also developing recombinant Fc multimer proteins to control inflammation associated with autoimmune diseases.

3D visualisation of DNA, double helix;

Gene and Cell Therapy

Through the acquisition of Calimmune Inc., CSL is focused on the development of ex vivo haematopoietic stem cell (HSC) gene therapy which has the potential to offer a significant advantage to patients suffering from currently incurable genetic diseases.

Cell and gene therapies are highly innovative, next-generation products that, after decades of research and development, are now starting to positively impact the lives of patients with serious diseases. For diseases with few effective therapeutic options, such as certain blood cell cancers, or where successful therapy has required a lifetime of regular symptomatic treatment, such as rare inherited genetic deficiencies, they offer the promise of a long-term cure.

The technology has the potential to be used in treatments for a wide range of rare diseases that would complement our business, including those within the company’s current product portfolio.

Seqirus scientist in a laboratory


Seqirus has leading R&D capabilities and a broad portfolio of differentiated products with commercial operations in over 20 countries. Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally.

Across our influenza portfolio, Seqirus has a number of clinical studies underway to expand age indications and further optimise adjuvant and cell-based technologies. Early stage collaborations are exploring other transformational approaches including universal influenza vaccine projects, synthetic seeds, yield optimisation and other vector/expression technologies.

These capabilities manifest themselves in the following therapeutic areas:

Woman with microscope


Our world-leading immunoglobulin (Ig) franchise is the cornerstone of the Immunology therapeutic area. Our efforts in this area focus on bringing trusted products and technologies to serve patients with a range of serious immunologic and neurologic diseases, including Primary and Secondary Immunodeficiencies (PID and SID) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). We are optimising patient experience and convenience through more flexible ways to dose and administer our existing intravenous and subcutaneous plasma-derived products.

Hand holding a pipet


CSL remains focused on easing the burden of care and improving the lives of patients with rare bleeding disorders. We are undertaking exciting research and development efforts to explore new indications in haematology as well as novel therapeutics in haemostasis and thrombosis. Our haemophilia research strategy is based on maximising the value and performance of our existing coagulation therapies and developing new protein-based therapies to treat bleeding disorders and increase the quality of life for patients.

Cardiovascular & Metabolic

The cardiovascular and metabolic therapeutic area is focused on improving and extending the lives of patients with cardiovascular disease (CVD) and diabetes.

picture of a gowned doctor in operating theatre operating on a person


Despite the remarkable advances in solid organ transplantation reflected by improved patient and graft survival rates, the treatment and management of solid organ transplant recipients remains a complex area of modern medicine. Organ transplant recipients are required to take life-long immunosuppressive medication to prevent their own immune systems from rejecting the donor organ (allograft). While current standard of care is very effective in the prevention and treatment of acute rejection, chronic rejection remains a high unmet medical need and is responsible for most cases of allograft failure.

Seqirus scientist in a laboratory

Influenza Vaccines

Developing new and better influenza vaccines across all age groups in expanded markets is a strategic priority for Seqirus, including further advancing our cell-based technology and our MF59® adjuvant as well as developing our self-amplifying messenger RNA (sa-mRNA) technology, to enhance the immune response of those particularly vulnerable to influenza such as children and older adults.

healthcare professionals


Chronic respiratory diseases impose an enormous burden on patients and society and are a leading cause of death and disability worldwide. To address this need, CSL is investigating new clinical treatments for respiratory diseases using our plasma derived immunoglobulins and proteins and novel recombinant monoclonal antibodies.